| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 1.44 | 0.01 (+0.70%) | 0.42 - 1.96 | 369.6 thousand (Below Avg) |
Market data as of 4:00PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 1.44 |
|---|---|
| Previous Close | 1.43 |
| Day's Range | 1.38 - 1.45 |
| Market Cap | 99.1M |
| Avg Volume (10 Day) | 1.0M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.16 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania
PR Newswire - Monday 05/20/2013 9:15 AM ET
Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In London
PR Newswire - Thursday 05/16/2013 9:15 AM ET
Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society Congress
PR Newswire - Monday 05/13/2013 9:15 AM ET
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
PR Newswire - Friday 05/10/2013 4:24 PM ET
Neuralstem ALS Trial Investigator And Patient On Sirius XM
PR Newswire - Wednesday 05/08/2013 9:15 AM ET
Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting
PR Newswire - Monday 04/29/2013 11:15 AM ET
Neuralstem And The National Football League Alumni Association Announce Initiative On Brain Injury Treatment
PR Newswire - Wednesday 04/24/2013 9:15 AM ET
| CUR | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -35.28% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 1.33 | |
| LT Debt/Equity | 1.24 | |
| Earnings Yield | -- | |
| Price/Sales | 277.95 |
| Company | Last | Change |
|---|---|---|
| Alcobra Ltd | 7.21 | -4.50% |
| Trovagene Inc | 6.95 | +9.62% |
| Biospecifics Technologies Corp | 15.87 | +1.60% |
| Nupathe Inc | 3.11 | -0.96% |
| Biota Pharmaceuticals Inc | 3.57 | -2.99% |
Data is delayed by at least 15 min.